Ari Gnanasakthy

3.0k total citations
87 papers, 2.0k citations indexed

About

Ari Gnanasakthy is a scholar working on Economics and Econometrics, Statistics and Probability and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Ari Gnanasakthy has authored 87 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Economics and Econometrics, 17 papers in Statistics and Probability and 14 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Ari Gnanasakthy's work include Health Systems, Economic Evaluations, Quality of Life (39 papers), Statistical Methods in Clinical Trials (15 papers) and Pharmaceutical studies and practices (12 papers). Ari Gnanasakthy is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (39 papers), Statistical Methods in Clinical Trials (15 papers) and Pharmaceutical studies and practices (12 papers). Ari Gnanasakthy collaborates with scholars based in United States, Switzerland and United Kingdom. Ari Gnanasakthy's co-authors include Carla DeMuro, Lynda Doward, Margaret Mordin, Marci Clark, S. V. Morant, Donald L. Patrick, Elisabeth Vodicka, K. Kim, John F. Scoggins and Mary Baker and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ari Gnanasakthy

84 papers receiving 1.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ari Gnanasakthy 634 339 223 215 200 87 2.0k
Marta Soares 926 1.5× 215 0.6× 496 2.2× 105 0.5× 91 0.5× 94 3.0k
Anthony S. Russell 133 0.2× 360 1.1× 158 0.7× 104 0.5× 241 1.2× 109 4.0k
Eldon Spackman 746 1.2× 141 0.4× 578 2.6× 172 0.8× 295 1.5× 102 2.7k
Gérard Duru 183 0.3× 134 0.4× 97 0.4× 60 0.3× 545 2.7× 70 1.8k
Carol Forbes 234 0.4× 373 1.1× 295 1.3× 115 0.5× 326 1.6× 34 1.9k
Michaël Schwarzinger 274 0.4× 248 0.7× 171 0.8× 80 0.4× 166 0.8× 85 3.1k
Charity Evans 199 0.3× 360 1.1× 116 0.5× 68 0.3× 249 1.2× 91 2.7k
James M. Bowen 235 0.4× 154 0.5× 153 0.7× 111 0.5× 150 0.8× 145 2.4k
Samuel Aballéa 331 0.5× 129 0.4× 133 0.6× 136 0.6× 202 1.0× 159 2.1k
D C Skegg 110 0.2× 675 2.0× 231 1.0× 289 1.3× 270 1.4× 81 3.1k

Countries citing papers authored by Ari Gnanasakthy

Since Specialization
Citations

This map shows the geographic impact of Ari Gnanasakthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari Gnanasakthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari Gnanasakthy more than expected).

Fields of papers citing papers by Ari Gnanasakthy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ari Gnanasakthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari Gnanasakthy. The network helps show where Ari Gnanasakthy may publish in the future.

Co-authorship network of co-authors of Ari Gnanasakthy

This figure shows the co-authorship network connecting the top 25 collaborators of Ari Gnanasakthy. A scholar is included among the top collaborators of Ari Gnanasakthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari Gnanasakthy. Ari Gnanasakthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gnanasakthy, Ari, et al.. (2021). Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019. Value in Health. 24(7). 1016–1023. 15 indexed citations
2.
Barrett, Amy, Julie Hahn-Pedersen, Nana Kragh, Emily Evans, & Ari Gnanasakthy. (2019). PSY52 PATIENT-REPORTED OUTCOME MEASURES IN ATOPIC DERMATITIS AND CHRONIC HAND ECZEMA IN ADULTS. Value in Health. 22. S911–S911. 1 indexed citations
3.
Gnanasakthy, Ari, et al.. (2019). A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016). Value in Health. 22(2). 203–209. 68 indexed citations
4.
Strober, Bruce, Alice B. Gottlieb, Bintu Sherif, et al.. (2017). Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal of the American Academy of Dermatology. 76(4). 655–661. 19 indexed citations
5.
Gnanasakthy, Ari, Margaret Mordin, Emily Evans, Lynda Doward, & Carla DeMuro. (2016). A Review of Patient-Reported Outcome Labeling in the United States (2011–2015). Value in Health. 20(3). 420–429. 35 indexed citations
6.
Gnanasakthy, Ari & Carla DeMuro. (2016). OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015). Value in Health. 19(3). A275–A275. 2 indexed citations
7.
Mahon, François‐Xavier, Carla Boquimpani, Naoto Takahashi, et al.. (2016). Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood. 128(22). 1891–1891. 10 indexed citations
8.
Copley‐Merriman, Catherine, et al.. (2016). Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development. Patient. 10(2). 203–213. 21 indexed citations
9.
Vodicka, Elisabeth, K. Kim, Beth Devine, et al.. (2015). Inclusion of Patient-Reported Outcome Measures In Registered Clinical Trials: Evidence From Clinicaltrials.Gov (2007-2013). Value in Health. 18(3). A209–A210. 84 indexed citations
10.
Copley‐Merriman, Catherine, et al.. (2015). Benefits of patient-reported outcomes in Dermatology Drug Development. Value in Health. 18(3). A184–A184. 1 indexed citations
11.
Winnette, Randall, et al.. (2015). Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems. Value in Health Regional Issues. 8. 49–55. 2 indexed citations
12.
Vodicka, Elisabeth, K. Kim, Emily Beth Devine, et al.. (2015). Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007–2013). Contemporary Clinical Trials. 43. 1–9. 160 indexed citations
13.
14.
15.
DeMuro, Carla, Marci Clark, Lynda Doward, et al.. (2013). Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006–2010). Value in Health. 16(8). 1150–1155. 59 indexed citations
16.
17.
Gnanasakthy, Ari, Lynda Doward, M. Clark, Margaret Mordin, & Carla DeMuro. (2012). PHP182 Concordance of PRO Labeling Claims Between the FDA and EMA. Value in Health. 15(7). A321–A321. 3 indexed citations
18.
DeMuro, Carla, M. Clark, Margaret Mordin, et al.. (2011). PHP96 REASONS FOR REJECTION OF PRO LABEL CLAIMS: AN ANALYSIS BASED ON A REVIEW OF PRO USE AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC LICENSE APPLICATIONS 2006-2010. Value in Health. 14(3). A29–A29. 3 indexed citations
19.
Mordin, Margaret, M. Clark, Carla DeMuro, et al.. (2011). PHP97 PRO LABEL CLAIMS: AN ANALYSIS BASED ON A REVIEW OF PROS AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC LICENSE APPLICATIONS 2006-2010. Value in Health. 14(3). A29–A29. 2 indexed citations
20.
Morant, S. V. & Ari Gnanasakthy. (1989). A new approach to the mathematical formulation of lactation curves. Animal Science. 49(2). 151–162. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Soares Breakdown of academic impact, for papers by Anthony S. Russell Breakdown of academic impact, for papers by Eldon Spackman Breakdown of academic impact, for papers by Gérard Duru Breakdown of academic impact, for papers by Carol Forbes Breakdown of academic impact, for papers by Michaël Schwarzinger Breakdown of academic impact, for papers by Charity Evans Breakdown of academic impact, for papers by James M. Bowen Breakdown of academic impact, for papers by Samuel Aballéa Breakdown of academic impact, for papers by D C Skegg
Rankless by CCL
2026